Exelixis | EXEL - Market Capitalization


Exelixis reported $12.64B in Market Capitalization this February of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.6B 10M Sep/2025
Agios Pharmaceuticals USD 1.6B 16M Feb/2026
Akebia Therapeutics USD 322M 180M Jun/2025
Amgen USD 201.45B 25.2B Feb/2026
AstraZeneca USD 222.33B 65.82B Feb/2026
Bayer EUR 27.23B 2.14B Sep/2025
BioMarin Pharmaceutical USD 11.99B 575M Feb/2026
Bristol-Myers Squibb USD 123.58B 13.77B Feb/2026
Cytokinetics USD 6.58B 2.63B Sep/2025
Eisai JPY 1.43T 119.2B Feb/2026
Eli Lilly USD 1.01T 3.37B Feb/2026
Esperion Therapeutics USD 340M 235M Dec/2023
Exelixis USD 12.27B 523M Feb/2026
Genmab DKK 80.88B 7.82B Jun/2025
Glaxosmithkline GBP 106.96B 20.08B Feb/2026
Incyte USD 22.7B 3.31B Feb/2026
Ionis Pharmaceuticals USD 10.43B 4.14B Sep/2025
MacroGenics USD 114M 8M Feb/2026
Merck USD 300.37B 39.11B Feb/2026
Moderna USD 16.5B 6.41B Feb/2026
Nektar Therapeutics USD 113M 4M Sep/2023
Neurocrine Biosciences USD 13.68B 465M Feb/2026
Novartis USD 265.66B 9.48B Sep/2025
Pfizer USD 152.89B 11.32B Feb/2026
Sanofi EUR 118.94B 1.6B Feb/2026
Takeda JPY 7.64T 774.9B Dec/2025
Ultragenyx Pharmaceutical USD 1.94B 284M Feb/2026
Xencor USD 837M 278M Sep/2025